

All Thyroid Ultrasound Evaluations are Not Equal: Sonographers Specialized in Thyroid Cancer Correctly Label Clinical N0 Disease in Well Differentiated Thyroid Cancer

Sarah C. Oltmann, MD, David F. Schneider, MD, MS, Herbert Chen, MD, and Rebecca S. Sippel, MD

Section of Endocrine Surgery, Department of Surgery, University of Wisconsin- Madison, Madison, WI

ABSTRACT

Background. Ultrasound (US) is a standard preoperative study in thyroid cancer. Accurate identification of lymph node (LN) disease in the central neck by US is debated, leading some surgeons to perform prophylactic central dissection. The purpose of this study was to evaluate if US performed by a surgeon with specialization in thyroid sonography correctly determined clinical N0 status.

Methods. Retrospective identification of cN0 thyroid cancer patients from a prospectively maintained database was performed. Exclusion criteria included LN dissection with thyroidectomy or missing preoperative US. Demographics and outcomes were reviewed. Patients were categorized by who performed the thyroid US (surgeon vs. non-surgeon). Additional radioactive iodine (RAI) treatments or subsequent positive pathology defined recurrence.

Results. From 2005 to 2012, 177 patients met criteria. Forty-eight patients had surgeon US versus 129 patients with non-surgeon US. Groups were equivalent in age, gender, and tumor size. Forty-six percent had a preoperative diagnosis of cancer, whereas 19 % had benign and 35 % had indeterminate diagnoses. Surgeon US documented LN status more frequently (69 vs. 20 %, $p < 0.01$). RAI treatment and dose were equivalent. RAI uptake was lower with surgeon US ($0.06 \% \pm 0.02$ vs. $0.20 \% \pm 0.03$, $p < 0.01$). Recurrence rates were higher in non-surgeon US

(12 vs. 0 %, $p = 0.01$). Median time to recurrence was 11 months.

Conclusions. Surgeons with thyroid US expertise correctly identify patients as N0, which may eliminate the need for prophylactic LN dissection without increasing risk of early recurrence. Because not all thyroid cancers are diagnosed preoperatively, US examination of the thyroid should include routine evaluation of the cervical LNs.

Cervical lymph node (LN) involvement in well-differentiated thyroid cancer (DTC) is common. For patients older than age 45 years, it also impacts staging.^{1,2} Preoperative physical exam and ultrasound (US) are the mainstays for determining LN involvement prior surgery, although occasionally suspicious central LNs are encountered at time of operation prompting a therapeutic central lymph node dissection (LND).^{1,3–8} Patients felt to be clinically node-negative (cN0) based on preoperative US do not need a therapeutic LND, although the use of prophylactic central LND in cN0 patients is hotly debated.^{9–11}

Currently, preoperative assessment of the cervical LN in thyroid cancer patients is performed via US due to increased sensitivity to detect metastatic involvement of LN compared with manual palpation.^{1,3–8,10} Traditionally, this assessment was performed by radiologists; however, in the recent decade, US has become a common tool for the surgeon and endocrinologist alike.^{3–5,7,12–22} Use of US during surgical training has become integrated into multiple different specialties: trauma, breast, abdominal, vascular, critical care, and head and neck surgery.²³ Because interpretation of US images can vary greatly, expertise in thyroid imaging as well as consistency of whom is performing the study results in optimal outcomes.^{11,15,16,24,25} Access to a specialized thyroid sonographer is not available at all institutions. In cases where the department of radiology does not have the

Poster Presentation at American Thyroid Association, San Juan, Puerto Rico, October 2013.

© Society of Surgical Oncology 2014

First Received: 21 March 2014;

Published Online: 19 September 2014

R. S. Sippel, MD

e-mail: sippel@surgery.wisc.edu

resources to dedicate a single individual or team with expertise in thyroid imaging, the surgeon sonographer with specialization in the care of thyroid cancer can provide consistency in interpretation and expertise in thyroid imaging.^{3,11,12,15,18,20,26}

The purpose of this study was to assess recurrence rates in cN0, DTC patients and to determine if surgeon-performed US in contrast to non-surgeon-performed US resulted in differences in early disease recurrence.

METHODS

With institutional review board approval, a retrospective review of a prospectively collected thyroid database at a large tertiary referral center was performed. Patients with cN0, DTC with a minimum of 6 months of follow-up were included. The diagnosis of DTC was based on either fine-needle aspiration (FNA) cytology or final surgical pathology. In some instances, the diagnosis of cancer was not known at time of US examination or surgery. Because institutional practice involves compartment-based LND for clinically N1a or N1b disease, patients undergoing LND, either central or lateral, at the time of initial thyroidectomy were excluded. Prophylactic LND of the central or lateral compartment for well-differentiated thyroid cancer is not performed at our institution. Patients without documented preoperative US were excluded. Patients found to have micropapillary thyroid cancer (PTC, <1 cm) were only included if an additional worrisome feature was noted on final pathology (multifocality, extrathyroidal extension, lymphovascular invasion, or positive margins).

Patients were categorized by who performed the US: the operative surgeon or a non-surgeon. The surgeon performing thyroid ultrasound had successfully completed the American College of Surgeons Head and Neck US course and currently serves as a course instructor. Surgeon-performed US occurred during initial clinic visit; occasionally these were repeated in the operating room prior incision. The study institution does not have a dedicated individual or team of radiologists who specialize in thyroid cancer; thyroid US is done by a variety of different radiologists with expertise in US but not necessarily thyroid cancer. To determine if the central and lateral compartments were assessed during US, the provider needed to specifically comment on LN with an associated descriptor as well as which compartments were evaluated. If no comment was specifically found regarding LN in both the central and lateral neck, the patient was classified as no LN evaluation.

Some patients had multiple tumor histologies on final pathology (i.e., PTC and follicular, PTC and Hurthle cell, etc.). For this reason, the frequency of each tumor type was totaled. Administration and dosing of radioactive iodine

ablation (RAI) was determined by the endocrinologists within the study institution. Patients were monitored for recurrence by endocrinology with suppressed thyroglobulin levels and an US examination at 6 months, followed by a stimulated thyroglobulin level and US examination at 1 year.¹ Diagnostic whole body scan was generally performed if US or thyroglobulin results were concerning for residual or recurrent disease. Follow-up after 1 year relied on annual suppressed thyroglobulin level and US evaluation of the neck. Disease recurrence was defined as the need for additional RAI treatment, as positive FNA or positive final pathology on operative reexploration. Staged lymph node dissections or staged completion thyroidectomies were not considered recurrences. Time to recurrence was calculated in months from time of initial operation to time of subsequent intervention (RAI or surgical resection).

Statistical analysis was performed using IBM SPSS Statistics, version 20.0. Pearson's χ^2 , Fisher's exact, and unpaired *t* tests were performed as appropriate. Kaplan-Meier survival analysis was performed with outcome listed as time to recurrence or time to last disease-free follow-up. Comparison of estimated disease-free curves was performed using Mantel-Cox log-rank. Data are expressed as mean \pm SE of the mean or as number (percentage) unless otherwise specified. A *p* value ≤ 0.05 was determined to be significant.

RESULTS

Between 2005 and 2012, 322 patients with cN0, DTC were identified. Seventy-three patients were excluded for less than 6 months follow-up available within the electronic medical record. An additional 59 patients with micro-PTC with low-risk features on histology (unifocal, intrathyroidal, no lymphovascular invasion, and negative margins) also were excluded. Finally, 13 (4 %) patients were noted to have no documented preoperative US, by either radiology report or by reference via clinician note and were excluded. The final study population was 177 patients.

The study population had an average age of 49 ± 1.1 years, and 73 % were female. Eighty-one patients (46 %) had a diagnosis of thyroid cancer before surgery, whereas 63 patients (35 %) had indeterminate biopsy results, and 34 patients (19 %) were undergoing surgery for a presumed benign condition (Graves', goiter, etc.). Surgeon-performed US occurred in 48 cases (27 %), whereas the remaining 129 patients (73 %) had a non-surgeon-performed US. Regardless of the sonographer (surgeon vs. non-surgeon), only 59 patients (33 %) had a full LN evaluation documented at time of US. However, the timing of the US may have occurred before the




FIG. 1 Breakdown of patients considered to have persistent and/or recurrent disease based on treatment and/or location/type of disease

TABLE 1 Patient preoperative demographic information

	Non-surgeon sonographer	Surgeon sonographer	<i>p</i> value
N	129	48	
Age (yrs)	50 ± 1.4	49 ± 2.2	0.75
Female	92 (71 %)	37 (77 %)	0.57
Preop diagnosis			0.28
Benign	23 (18 %)	11 (23 %)	
Indeterminate	43 (33 %)	20 (42 %)	
Malignant	63 (49 %)	17 (35 %)	
Documented assessment of cervical lymph nodes with US	26 (20 %)	33 (69 %)	<0.01

Data expressed as mean ± SE of the mean or number (percentage) unless otherwise indicated, *p* values in bold denote statistical significance

diagnosis of cancer was established. Overall, 14 recurrences (8 %) were noted (Fig. 1).

Patients were grouped based on who performed their US evaluation: surgeon or non-surgeon. Patient age ($p = 0.77$) and gender ($p = 0.57$) were equivalent between groups (Table 1). The preoperative diagnosis based on FNA results and/or clinical diagnosis (i.e., Graves') were of similar distribution of benign, indeterminate, and malignant between groups ($p = 0.26$). Patients with a surgeon-performed US were much more likely to have evaluation of their cervical LN than those patients undergoing ultrasound

evaluation by a non-surgeon provider (69 vs. 20 %, $p < 0.01$).

With the exception of the surgeon-performed US group having a higher incidence of follicular thyroid carcinoma (19 vs. 4 %, $p < 0.01$), the groups had equal rates of PTC ($p = 0.21$), Hürthle cell carcinoma ($p = 1$), and background thyroiditis ($p = 0.60$; Table 2). The surgeon-performed US group had a greater incidence of lymphovascular invasion noted on histology (13 vs. 3 %, $p = 0.03$), whereas the remaining histologic characteristics of the primary tumor were equivalent. On final pathology, tumor size ($p = 0.13$) and total gland weight ($p = 0.93$) did not differ.

RAI was used with equal frequency ($p = 0.41$) and equivalent doses ($p = 0.31$; Table 3). Median follow-up was shorter in the surgeon-performed US group (20 vs. 34 months, $p < 0.01$). However, median time to recurrence was 11 months, with first recurrence detected at 6 months and last recurrence detected at 6 years. Only two recurrences were diagnosed beyond 15 months and occurred between 4 and 6 years after initial surgery. Of the remaining patients, disease was detected within the first year from surgery in seven, and in five patients, shortly after the 1 year anniversary of their initial operation. No patient in the surgeon-performed US group had evidence of disease recurrence at time of last follow-up compared with 14 patients (12 %) in the non-surgeon-performed US group ($p = 0.01$).

Grouping patients based on if the operative surgeon performed an US evaluation of the neck, a Kaplan–Meier curve for disease-free interval was constructed (Fig. 2a). Patients having US exam performed only by a non-surgeon were disease-free 94 % at 1 year, 89 % at 2 years, and 87 % at 5 years. This was in marked contrast to the group with surgeon-performed US who were disease-free 100 % at 1, 2, and 5 years ($p = 0.04$). To ensure that the specialty of the individual performing the US evaluation was not a confounder for LN assessment, an additional analysis specific to documented LN assessment also was performed (Fig. 2b). Estimated disease-free status did not differ between these groups ($p = 0.66$).

DISCUSSION

In the hands of an experienced thyroid surgeon, trained in thyroid US, the classification of a patient as cN0 and forgoing prophylactic LND resulted in no recurrences to date, with actuarial follow-up to 5 years. In contrast, patients undergoing a non-surgeon US experienced a recurrence rate of 12 %, with 86 % of recurrences occurring within the first 15 months of diagnosis. This early time to recurrence is suggestive of unrecognized disease present

TABLE 2 Tumor type and pathologic characteristics

	Non-surgeon sonographer	Surgeon sonographer	<i>p</i> value
N	129	48	
Tumor type			
Papillary	121 (94 %)	42 (88 %)	0.21
Follicular	5 (4 %)	9 (19 %)	<0.01
Hürthle carcinoma	5 (4 %)	1 (2 %)	1.0
Micro PTC	26 (20 %)	8 (17 %)	0.39
Pathologic characteristics			
Multifocal	75 (58 %)	30 (63 %)	0.73
Extrathyroidal extension	13 (10 %)	4 (8 %)	1.0
Positive margin	8 (6 %)	3 (7 %)	1.0
Lymphovascular invasion	4 (3 %)	6 (13 %)	0.03
Lymphocytic thyroiditis	44 (34 %)	19 (40 %)	0.60
Tumor size (cm)	1.8 ± 0.1	2.2 ± 0.2	0.13
Size of micro PTC (cm)	0.6 ± 0.05	0.6 ± 0.07	0.71
Gland weight (g)	25 ± 3.9	26 ± 2.6	0.92

Data expressed as number (percentage) or as mean ± SE of the mean unless otherwise indicated, *p* values in bold denote statistical significance

TABLE 3 Postoperative management and disease specific outcomes

	Non-surgeon sonographer	Surgeon sonographer	<i>p</i> value
RAI	114 (88 %)	45 (94 %)	0.41
RAI Dose (mCi)	83 ± 5	93 ± 6	0.31
Remnant Uptake	0.2 ± 0.03	0.06 ± 0.02	<0.01
Follow Up (Months)	34 (16-64)	20 (10-34)	<0.01
Disease Recurrence	14 (12 %)	0	0.01
Time to Recurrence (Months)	11 (6.6)	0	<0.01

Data expressed as number (percentage), mean ± SE of the mean, or median (interquartile range) as appropriate, *p* values in bold denote statistical significance

at time of initial diagnosis, or persistent disease. These data also support previous reports that a negative US of the central neck by experienced sonographers predicts long-term regional control and that the microscopic disease found during prophylactic dissection may not impact short-term disease-free survival.^{10,11,27,28}


US is a highly operator-dependent modality and variability in image interpretation between sonographers is problematic.^{15,16,24,25,29} Rosario evaluated US assessment of the cervical LN during surveillance in patients with known high-risk PTC.²⁹ Radiologists at a diagnostic imaging center, without specific specialization in thyroid imaging, missed half of the cervical metastasis caught 2 weeks later by a specialized thyroid sonographer. Previous work from this institution, as well as from other authors, has described the omission of LN commentary on thyroid US reports, even when the evaluation of the cervical LN were specifically requested.^{3,26,29,30} For purposes of this study, patients with omitted LN commentary were classified as not having the assessment performed.

Surgeons have access to all pertinent clinical information at time of US, excellent understanding of the local anatomy, as well as feedback from final pathologic results to continue to learn the finer nuances of ultrasound findings within the neck.^{3,4,15,18,20} Radiology educational literature emphasizes the importance of repetition, in addition to familiarity with the key imaging characteristics, for greater accuracy of thyroid US interpretation.^{24,25} Thyroid surgeons, by using US weekly in both the clinic and operating room, can quickly develop the skills needed to perform thyroid US proficiently and accurately.


The timing of thyroid US during the course of patient workup also may influence image interpretation. During a thyroid nodule workup, US and thyroid function tests are initially ordered.¹ As the patient is deemed to need further evaluation and if necessary, referral for endocrinology or surgical consultation, the underlying index of suspicion for malignancy increases. At this time, a provider specialized in the care of thyroid cancer can scrutinize the US characteristics of the nodule, the remaining thyroid, as well as

FIG. 2 Disease-free status. **a** Based on who performed the preoperative ultrasound evaluation. **b** Based on whether preoperative ultrasound evaluation included a lymph node assessment

A Patients Disease Free – Surgeon Performed US vs Non-Surgeon Performed US



B Patients Disease Free – Node Evaluation by US vs Non Node Evaluation by US



assess LN appearance. These variables can be placed within the context of the patient history, physical findings, and biopsy results to formulate an opinion regarding both the suspicion for malignancy and LN involvement.^{3,7,20,31} The findings of improved short-term disease-free survival with surgeon US within this study are supportive of this as well.

Only 46 % of our study population had an established diagnosis of cancer before surgery, which likely influenced the extent of the preoperative ultrasound evaluation. The remainder of patients had indeterminate or benign pathologies, requiring operative intervention. Given these

nonmalignant diagnoses, under current guidelines, LN assessment would not be indicated.³² However, when patients undergo a diagnostic lobectomy for indeterminate cytology, and final pathology returns as malignant, LN assessment in a recently operated neck may be less reliable. Findings of suspicious cervical lymphadenopathy in the setting of suspicious or indeterminate cytology may prompt additional evaluation and confirm the diagnosis of malignancy in time to alter the operative plan.^{3,30,33}

LN assessment is recommended to occur via physical exam at the initial stage of thyroid nodule workup; however, studies have shown that US is superior to physical

exam in detecting worrisome LN.^{1,7,8,33,34} For these reasons, the authors advocate the routine cervical LN assessment with clear documentation of findings during initial thyroid US.^{2-4,20,35} Evaluation of the LN at time of initial thyroid US would not add a substantial amount of time to the examination and would streamline care by avoiding additional appointments for dedicated LN assessment.¹⁸ Results of this study have prompted ongoing quality improvement and continuing medical education within the study institution, as well as the surrounding medical community, emphasizing the importance of lymph node involvement at time of thyroid US.

Management of thyroid cancer requires a strong interdisciplinary team to facilitate the diagnosis, management, and long-term follow-up. Dedicated endocrinologists, surgeons, radiologist, and nuclear medicine physicians are critical to ensure a successful thyroid cancer program.⁶ However, not every institution has all of these resources at their disposal, and overlapping skill sets between the providers may be necessary.^{12,20,33} While these results are specific to surgeon performed US within the study institution, a dedicated thyroid sonographer of any specialty could achieve comparable outcomes.

Because this study is retrospective in nature, it has its inherent flaws. The study population consists of only patients with negative findings on US, who did not undergo LN excision. Given the initial patient selection based on an absence of LND at time of initial surgery, as well as the presence of cancer on final pathology, it is unknown how many patients had negative US imaging, but during thyroidectomy suspicious LN were encountered prompting subsequent LND. Therefore, sensitivity, specificity, positive, or negative predictive value of US on the detection of LN metastases cannot be calculated. While clinically significant disease was not identified in follow-up, this does not equate to the absence of microscopic disease. The length of follow-up included can attest to early recurrence or persistence, but long-term (>5 year) outcomes cannot be assumed based on these data. Ongoing data collection for these cohorts of patients is being performed to see how long-term recurrence rates may differ between the cohorts. This also will determine the durability of the initial US evaluation.

While the study population does not differ in basic patient demographics, they are inherently different by the mere fact that a portion of the non-surgeon group includes patients erroneously categorized as cN0 who with follow-up have evidence of persistent disease. This disease was likely present at time of initial preoperative consultation but was missed. Patients undergoing surgeon US had this disease initially detected and were able to undergo therapeutic LND. However, this very fact drives home the point that surgeon US can correctly stratify patients before operative intervention.

CONCLUSIONS

We demonstrated that a surgeon sonographer with expertise in thyroid cancer can provide an accurate assessment of the LN status in both the central and lateral neck, as demonstrated by the 100 % disease-free status at time of last follow-up. This implies that a thorough US examination of the cervical LN can detect clinically relevant disease in DTC. A negative, high-quality US of the cervical LN may obviate the need for a prophylactic central LND. Because not all patients have an established diagnosis of cancer at time of thyroid US, additional information provided by a LN evaluation can lead to the correct diagnosis. Assessment of the cervical LN should be a standard part of any thyroid US. It is critical that an experienced sonographer provide this assessment to enable the proper extent of surgery and reduce early recurrence.

REFERENCES

1. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*. 2009;19(11):1167-214.
2. American Thyroid Association Surgery Working G, American Association of Endocrine S, American Academy of O-H, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid*. 2009;19(11):1153-8.
3. Mazzaglia PJ. Surgeon-performed ultrasound in patients referred for thyroid disease improves patient care by minimizing performance of unnecessary procedures and optimizing surgical treatment. *World J Surg*. 2010;34(6):1164-70.
4. Milas M, Stephen A, Berber E, Wagner K, Miskulin J, Siperstein A. Ultrasonography for the endocrine surgeon: a valuable clinical tool that enhances diagnostic and therapeutic outcomes. *Surgery*. 2005;138(6):1193-1200; discussion 1200-1.
5. Miller BS, Gauger PG, Broome JT, Burney RE, Doherty GM. An international perspective on ultrasound training and use for thyroid and parathyroid disease. *World J Surg*. 2010;34(6):1157-63.
6. Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. *CA Cancer J Clin*. 2013;63(6):374-94.
7. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL 3rd. Surgeon-performed ultrasound in the management of thyroid malignancy. *Am Surg*. 2004;70(7):576-80; discussion 580-2.
8. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery*. 2003;134(6):946-54; discussion 954-5.
9. Carling T, Carty SE, Ciarleglio MM, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. *Thyroid*. 2012;22(3):237-44.
10. Randolph GW, Duh Q-Y, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. *Thyroid*. 2012;22(11):1144-52.
11. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but

- negative findings predict excellent long-term regional control and survival. *Thyroid*. 2012;22(4):347–55.
12. Al-azawi D, Mann GB, Judson RT, Miller JA. Endocrine surgeon-performed US guided thyroid FNAC is accurate and efficient. *World J Surg*. 2012;36(8):1947–52.
 13. Choi JS, Chung WY, Kwak JY, Moon HJ, Kim MJ, Kim EK. Staging of papillary thyroid carcinoma with ultrasonography: performance in a large series. *Ann Surg Oncol*. 2011;18(13):3572–8.
 14. Goldfarb M, Gondek SS, Sanchez Y, Lew JI. Clinic-based ultrasound can predict malignancy in pediatric thyroid nodules. *Thyroid*. 2012;22(8):827–31.
 15. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *Laryngoscope*. 2011;121(3):487–91.
 16. Kabaker AS, Tublin ME, Nikiforov YE, et al. Suspicious Ultrasound Characteristics Predict BRAFV600E-Positive Papillary Thyroid Carcinoma. *Thyroid*. 2012;22(6):585–9.
 17. Kangelaris GT, Kim TB, Orloff LA. Role of ultrasound in thyroid disorders. *Otolaryngol Clin N Am*. 2010;43(6):1209–27, vi.
 18. Lee CY, Snyder SK, Lairmore TC, Dupont SC, Jupiter DC. Utility of surgeon-performed ultrasound assessment of the lateral neck for metastatic papillary thyroid cancer. *J Oncol*. 2012;2012:973124.
 19. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. *Endocr Pract*. 2005;11(1):49–54.
 20. Mendez W, Rodgers SE, Lew JI, Montano R, Solorzano CC. Role of surgeon-performed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules. *Ann Surg Oncol*. 2008;15(9):2487–92.
 21. Akinci B, Demir T, Yener S, et al. Beneficial effect of endocrinologist-performed ultrasonography on preoperative parathyroid adenoma localization. *Endocr Pract*. 2009;15(1):17–23.
 22. Zangeneh F, Powell CC, Gharib H. A survey on the use of thyroid ultrasonography in clinical endocrinology training programs. *Endocr Pract*. 2003;9(2):162–3.
 23. Rozycki GS. Surgeon-performed ultrasound: its use in clinical practice. *Ann Surg*. 1998;228(1):16–28.
 24. Kim HG, Kwak JY, Kim EK, Choi SH, Moon HJ. Man to man training: can it help improve the diagnostic performances and interobserver variabilities of thyroid ultrasonography in residents? *Eur J Radiol*. 2012;81(3):e352–6.
 25. Kim SH, Park CS, Jung SL, et al. Observer variability and the performance between faculties and residents: US criteria for benign and malignant thyroid nodules. *Korean J Radiol*. 2010;11(2):149–55.
 26. Poehls JL, Chen H, Sippel RS. Preoperative ultrasonography findings predict the need for repeated surgery in papillary thyroid cancer. *Endocr Pract*. 2012;18(3):403–9.
 27. Shen WT, Ogawa L, Ruan D, Suh I, Duh QY, Clark OH. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. *Surgery*. 2010;148(2):398–403.
 28. Raffaelli M, De Crea C, Sessa L, et al. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. *Surgery*. 2012;152(6):957–64.
 29. Rosario PW. Ultrasonography for the follow-up of patients with papillary thyroid carcinoma: how important is the operator? *Thyroid*. 2010;20(7):833–4.
 30. Roy R, Kouniavsky G, Venkat R, et al. The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules. *J Surg Oncol*. 2012;105(6):601–5.
 31. Sippel RS, Elaraj DM, Khanafshar E, Kebebew E, Duh QY, Clark OH. Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid? *Surgery*. 2007;142(6):851–7; discussion 857 e851–2.
 32. AIUM Practice Guideline for the performance of ultrasound examinations of the head and neck. *J Ultrasound Med*. 2014;33(2):366–82.
 33. Lew JI, Solorzano CC. Use of ultrasound in the management of thyroid cancer. *Oncologist*. 2010;15(3):253–8.
 34. Giacomini CP, Jeffrey RB, Shin LK. Ultrasonographic evaluation of malignant and normal cervical lymph nodes. *Semin Ultrasound CT MR*. 2013;34(3):236–47.
 35. Stack BC, Jr., Ferris RL, Goldenberg D, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. *Thyroid*. 2012;22(5):501–8.